Literature DB >> 21768582

Communicating data about the benefits and harms of treatment: a randomized trial.

Steven Woloshin1, Lisa M Schwartz.   

Abstract

BACKGROUND: Despite limited evidence, it is often asserted that natural frequencies (for example, 2 in 1000) are the best way to communicate absolute risks.
OBJECTIVE: To compare comprehension of treatment benefit and harm when absolute risks are presented as natural frequencies, percents, or both.
DESIGN: Parallel-group randomized trial with central allocation and masking of investigators to group assignment, conducted through an Internet survey in September 2009. (ClinicalTrials.gov registration number: NCT00950014)
SETTING: National sample of U.S. adults randomly selected from a professional survey firm's research panel of about 30,000 households. PARTICIPANTS: 2944 adults aged 18 years or older (all with complete follow-up). INTERVENTION: Tables presenting absolute risks in 1 of 5 numeric formats: natural frequency (x in 1000), variable frequency (x in 100, x in 1000, or x in 10,000, as needed to keep the numerator >1), percent, percent plus natural frequency, or percent plus variable frequency. MEASUREMENTS: Comprehension as assessed by 18 questions (primary outcome) and judgment of treatment benefit and harm.
RESULTS: The average number of comprehension questions answered correctly was lowest in the variable frequency group and highest in the percent group (13.1 vs. 13.8; difference, 0.7 [95% CI, 0.3 to 1.1]). The proportion of participants who "passed" the comprehension test (≥13 correct answers) was lowest in the natural and variable frequency groups and highest in the percent group (68% vs. 73%; difference, 5 percentage points [CI, 0 to 10 percentage points]). The largest format effect was seen for the 2 questions about absolute differences: the proportion correct in the natural frequency versus percent groups was 43% versus 72% (P < 0.001) and 73% versus 87% (P < 0.001). LIMITATION: Even when data were presented in the percent format, one third of participants failed the comprehension test.
CONCLUSION: Natural frequencies are not the best format for communicating the absolute benefits and harms of treatment. The more succinct percent format resulted in better comprehension: Comprehension was slightly better overall and notably better for absolute differences. PRIMARY FUNDING SOURCE: Attorney General Consumer and Prescriber Education grant program, the Robert Wood Johnson Pioneer Program, and the National Cancer Institute.

Entities:  

Mesh:

Year:  2011        PMID: 21768582     DOI: 10.7326/0003-4819-155-2-201107190-00004

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  34 in total

1.  Visual presentations of efficacy data in direct-to-consumer prescription drug print and television advertisements: A randomized study.

Authors:  Helen W Sullivan; Amie C O'Donoghue; Kathryn J Aikin; Dhuly Chowdhury; Rebecca R Moultrie; Douglas J Rupert
Journal:  Patient Educ Couns       Date:  2015-12-22

Review 2.  Assessment of fracture risk.

Authors:  Sanford Baim; William D Leslie
Journal:  Curr Osteoporos Rep       Date:  2012-03       Impact factor: 5.096

3.  The Drug Facts Box: Improving the communication of prescription drug information.

Authors:  Lisa M Schwartz; Steven Woloshin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-13       Impact factor: 11.205

4.  The price of false beliefs: unrealistic expectations as a contributor to the health care crisis.

Authors:  Steven H Woolf
Journal:  Ann Fam Med       Date:  2012 Nov-Dec       Impact factor: 5.166

5.  Getting to better prescription drug information.

Authors:  Steven Woloshin; Lisa M Schwartz
Journal:  J Gen Intern Med       Date:  2012-12       Impact factor: 5.128

6.  Consumers' Understanding of FDA Approval Requirements and Composite Scores in Direct-to-Consumer Prescription Drug Print Ads.

Authors:  Amie C O'Donoghue; Helen W Sullivan; Pamela A Williams; Claudia Squire; Kevin R Betts; Jessica Fitts Willoughby; Sarah Parvanta
Journal:  J Health Commun       Date:  2016-07-14

Review 7.  Pharmaceutical Benefit-Risk Communication Tools: A Review of the Literature.

Authors:  Dominic Way; Hortense Blazsin; Ragnar Löfstedt; Frederic Bouder
Journal:  Drug Saf       Date:  2017-01       Impact factor: 5.606

8.  Understandability of Patient Information Booklets for Patients with Cancer.

Authors:  Christian Keinki; Richard Zowalla; Martin Wiesner; Marie Jolin Koester; Jutta Huebner
Journal:  J Cancer Educ       Date:  2018-06       Impact factor: 2.037

9.  Association of Preferences for Papillary Thyroid Cancer Treatment With Disease Terminology: A Discrete Choice Experiment.

Authors:  Brooke Nickel; Kirsten Howard; Juan P Brito; Alexandra Barratt; Ray Moynihan; Kirsten McCaffery
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-10-01       Impact factor: 6.223

10.  Communicating Benefit and Risk Information in Direct-to-Consumer Print Advertisements: A Randomized Study.

Authors:  Helen W Sullivan; Amie C O'Donoghue; Kathryn J Aikin
Journal:  Ther Innov Regul Sci       Date:  2015-07       Impact factor: 1.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.